Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.
Part 2.1: Price Behavior Around Earnings
Amphastar typically reports earnings after the market close, meaning Day 0 reflects anticipation before results are released, while Day +1 captures the market's first full reaction to the actual numbers.
| Earnings Date | Day 0 Move | Day 0 Range | Day +1 Move | Day +1 Range |
|---|---|---|---|---|
| 2026-08-06 | -$0.43 (-2.12%) | $0.65 (3.20%) | +$0.97 (+4.90%) | $2.25 (11.33%) |
| 2026-05-07 | +$0.13 (+0.54%) | $0.47 (1.99%) | -$5.03 (-20.93%) | $1.24 (5.18%) |
| 2026-02-26 | -$1.48 (-5.29%) | $1.90 (6.81%) | -$6.26 (-23.63%) | $3.44 (12.97%) |
| 2025-11-06 | -$1.08 (-4.27%) | $1.38 (5.45%) | -$0.20 (-0.83%) | $3.73 (15.39%) |
| 2025-08-07 | +$0.80 (+3.84%) | $1.04 (4.99%) | +$2.19 (+10.13%) | $2.63 (12.16%) |
| 2025-05-07 | +$0.56 (+2.35%) | $0.66 (2.79%) | +$0.22 (+0.90%) | $1.68 (6.88%) |
| 2025-02-27 | +$0.28 (+0.90%) | $0.70 (2.24%) | -$3.06 (-9.72%) | $3.18 (10.10%) |
| 2024-11-06 | +$1.84 (+3.57%) | $1.91 (3.69%) | -$7.31 (-13.69%) | $3.42 (6.40%) |
| Avg Abs Move | 2.86% | 3.89% | 10.59% | 10.05% |
Amphastar's stock has exhibited significant volatility around earnings events, with an average absolute Day +1 move of 10.59%—well above typical market reactions and reflecting the company's exposure to product-specific surprises and competitive dynamics.
The most recent earnings event (August 2026) saw a modest Day 0 decline of 2.12%, followed by a strong Day +1 gain of 4.90%, consistent with the significant earnings beat. The prior quarter (May 2026) showed minimal Day 0 movement (+0.54%) but a dramatic Day +1 collapse of 20.93%, reflecting the severe earnings miss and BAQSIMI pricing shock. The February 2026 report saw a 5.29% Day 0 decline followed by a 23.63% Day +1 drop, compounding the negative reaction to disappointing results.
The historical pattern shows that negative surprises have triggered particularly severe reactions, with Day +1 moves exceeding 20% in two of the past four quarters. Positive surprises have generated more moderate upside, with the August 2026 beat producing a 4.90% Day +1 gain. The Day 0 average move of 2.86% suggests limited pre-announcement positioning, while the Day +1 average of 10.59% indicates that the bulk of price action occurs after results are digested.
Given the elevated historical volatility and the company's recent track record of large beats and misses, investors should expect meaningful post-earnings movement. The direction will likely hinge on whether BAQSIMI pricing shows tangible improvement from remediation efforts and whether ipratropium bromide revenue meets elevated expectations.
Part 2.2: Options Market Expected Move
| Metric | Value |
|---|---|
| Expiration Date | 11/20/26 (DTE 16) |
| Expected Move | $0.94 (3.34%) |
| Expected Range | $27.07 to $28.94 |
| Implied Volatility | 104.24% |
The options market is pricing a 3.34% expected move for Amphastar through the November 20 expiration, implying a range of $27.07 to $28.94. This is significantly below the stock's historical average Day +1 earnings move of 10.59%, suggesting options traders may be underpricing potential volatility. The historical Day 0 range of 3.89% is roughly in line with the options expectation, but the Day +1 range of 10.05% is more than three times larger, indicating the market may be underestimating the potential for a sharp post-earnings reaction based on recent precedent.
Part 3: What Analysts Are Saying
Analyst sentiment on Amphastar is decidedly cautious, with a consensus rating that leans toward the bearish end of the spectrum. The current average recommendation stands at 2.88, which falls between Sell (2) and Hold (3), reflecting skepticism about near-term prospects.
The breakdown shows 7 Hold ratings and 1 Moderate Sell, with no Buy or Strong Buy recommendations among the 8 analysts covering the stock. This unanimous absence of bullish ratings is notable and suggests the analyst community is taking a wait-and-see approach as the company navigates its strategic transition and pricing headwinds.
The average price target of $22.50 implies downside of approximately 19.7% from the current price of $28.02, with estimates ranging from a low of $20.00 to a high of $30.00. The wide spread reflects divergent views on how quickly the company can resolve BAQSIMI pricing issues and whether new product launches can offset legacy product pressures.
Analyst sentiment has remained unchanged over the past month, with the rating holding steady at 2.88 and the same 7 Hold / 1 Sell distribution. This stability suggests analysts are maintaining their cautious stance heading into the earnings report, awaiting evidence that the company's remediation efforts and new launches are gaining meaningful traction. The lack of positive revisions despite the strong Q2 beat indicates lingering concerns about sustainability and the path to margin recovery.
Part 4: Technical Picture
Amphastar is entering earnings with strong technical momentum, supported by positive signals across multiple timeframes. The Barchart Technical Opinion currently shows a 100% Buy signal, up from 80% a week ago and 88% a month ago, indicating accelerating bullish momentum as the stock has rallied into the report.
Timeframe Analysis:
- Short-term (100% Buy): Strong buy signal indicates near-term momentum is decisively positive, reflecting the stock's recent rally above key moving averages
- Medium-term (100% Buy): Bullish reading suggests the intermediate-term trend has turned positive, supporting the case for continued strength
- Long-term (100% Buy): Strong buy signal reflects improving longer-term trend structure as the stock recovers from earlier 2026 weakness
Trend Characteristics: The signal strength is characterized as Strong with direction described as Strongest, indicating robust and accelerating upward momentum heading into the earnings event.
The stock is trading at $28.02, positioned above all major moving averages: the 5-day ($27.36), 10-day ($26.54), 20-day ($26.36), 50-day ($25.11), 100-day ($22.59), and 200-day ($22.27). This clean alignment with the stock above every key average is a textbook bullish setup, suggesting strong underlying demand and a well-established uptrend.
| Period | Value | Period | Value |
|---|---|---|---|
| 5-Day MA | $27.36 | 50-Day MA | $25.11 |
| 10-Day MA | $26.54 | 100-Day MA | $22.59 |
| 20-Day MA | $26.36 | 200-Day MA | $22.27 |
The technical picture is unambiguously supportive heading into earnings, with the stock trading near recent highs and showing broad-based strength across all timeframes. The 25.8% gain from the 200-day moving average reflects a significant recovery from the first-quarter lows, when BAQSIMI pricing concerns weighed heavily on sentiment. The 11.6% premium to the 50-day average suggests the recent rally has been sustained rather than a short-term spike.
However, the bullish technical setup creates a potential risk: with the stock already up sharply and trading above all moving averages, much of the good news may already be priced in. The disconnect between the technical strength (100% Buy) and analyst sentiment (average target implying 19.7% downside) is striking and suggests the market is pricing in significant optimism about the company's ability to execute on its turnaround. A disappointment on BAQSIMI remediation progress or weaker-than-expected ipratropium bromide uptake could trigger a sharp reversal, particularly given the stock's historical tendency toward large post-earnings moves. Conversely, if results confirm that the Q2 momentum is sustainable, the technical setup supports further upside with limited overhead resistance.